Development of a specially tailored local drug delivery system for the prevention of fibrosis after insertion of cochlear implants into the inner ear

Journal of Materials Science: Materials in Medicine

Volumn 23, Issue 9, 2012, Pages 2151-2162

  Bohl, Anne ^a   Rohm, Henning W ^a   Ceschi, Piera ^b   Paasche, Gerrit ^b   Hahn, Anne ^c   Barcikowski, Stephan ^c   Lenarz, Thomas ^b   Stöver, Timo ^d   Pau, Hans Wilhelm ^a   Schmitz, Klaus Peter ^a   Sternberg, Katrin ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c LASER ZENTRUM HANNOVER E V   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COATING STABILITY; DEXAMETHASONES; FIBROTIC TISSUE; GANGLION CELLS; IN-VITRO; INNER EAR; LOCAL DRUG DELIVERY; POLYMERIC COATINGS; QUASI-STATIONARY; SIGNAL TRANSMISSION;

BIOCOMPATIBILITY; DRUG DELIVERY; DRUG PRODUCTS; SILICONE COATINGS; SILICONES;

COCHLEAR IMPLANTS;

DEXAMETHASONE; SILICONE;

ANIMAL CELL; ARTICLE; COCHLEA PROSTHESIS; COCHLEAR IMPLANT ASSOCIATED LOCAL DRUG DELIVERY SYSTEM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; FIBROSIS; IN VITRO STUDY; INNER EAR; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; CELL SURVIVAL; CELLS, CULTURED; COATED MATERIALS, BIOCOMPATIBLE; COCHLEAR IMPLANTATION; COCHLEAR IMPLANTS; DRUG DELIVERY SYSTEMS; EAR, INNER; FIBROSIS; INJECTIONS, INTRALESIONAL; MATERIALS TESTING; ORGAN SPECIFICITY; OXYGEN; POSTOPERATIVE COMPLICATIONS; RATS; RATS, SPRAGUE-DAWLEY; SILICONES; SPIRAL GANGLION;

EID: 84867101014     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-012-4698-z     Document Type: Article

References (29)

1. Van de Water TR, Dinh CT, Vivero R, Hoosien G, Eshraghi AA, Balkany TJ. Mechanism of hearing loss from trauma and inflammation: otoprotective therapies from the laboratory to the clinic. Acta Otolaryngol. 2010;130(3):308-11.
2. Furze A, Kralick D, Vakharia A, Jaben K, Graves R, Adil E, Eshraghi AA, Balkany TJ, Van de Water TR. Dexamethasone and methylprednisolone do not inhibit neuritic outgrowth while inhibiting outgrowth of fibroblasts from spiral ganglion explants. Acta Otolaryngol. 2008;128:122-7.
3. Paasche G, Bockel F, Tasche C, Lesinski-Schiedat A, Lenarz T. Changes of postoperative impedances in cochlear implant patients: the short-Term effects of modified electrode surfaces and intracochlear corticosteroids. Otol Neurotol. 2006;27:639-47.
4. Hargunani CA, Kempton JB, DeGagne JM, Trune DR. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol. 2006;27:564-9.
5. Bird PA, Murray DP, Zhang M, Begg EJ. Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph. Otol Neurotol. 2011;32:933-6.
6. Braun S, Ye Q, Radeloff A, Kiefer J, Gstoettner W, Tillein J. Protection of inner ear function after cochlear implantation: compound action potential measurements after local application of glucocorticoids in the guinea pig cochlea. ORL J Otorhinolaryngol Relat Spec. 2011;73:219-28.
7. Rajan G, Kuthubutheen J, Hedne N, Krishnaswamy J. The role of preoperative, intratympanic glucocorticoids for hearing preservation in cochlear implantation: a prospective clinical study. Laryngoscope. 2012;122:190-5.
8. Borden RC, Saunders JE, Berryhill WE, Krempl GA, Thompson DM, Queimado L. Hyaluronic acid hydrogel sustains the delivery of dexamethasone across the round window membrane. Audiol Neurootol. 2011;16:1-11.
9. Eastwood H, Chang A, Kel G, Sly D, Richardson R, O'Leary SJ. Round window delivery of dexamethasone ameliorates local and remote hearing loss produced by cochlear implantation into the second turn of the guinea pig cochlea. Hear Res. 2010;265:25-9.
10. Salt AN, Plontke SK. Local inner-ear drug delivery and pharmacokinetics. Drug Discov Today. 2005;10:1299-306.
11. Maini S, Lisnichuk H, Eastwood H, Pinder D, James D, Richardson RT, Chang A, Connolly T, Sly D, Kel G, O'Leary SJ. Targeted therapy of the inner ear. Audiol Neurootol. 2009;14: 402-10.
12. Souter M, Eastwood H, Marovic P, Kel G, Wongprasartsuk S, Ryan AF, O'Leary SJ. Systemic immunity influences hearing preservation in cochlear implantation. Otol Neurotol. 2012; 33(4):532-8.
13. Arnold W, Senn P, Hennig M, Michaelis C, Deingruber K, Scheler R, Steinhoff HJ, Riphagen F, Lamm K. Novel slow-And fast-Type drug release round-window microimplants for local drug application to the cochlea: an experimental study in guinea pigs. Audiol Neurootol. 2005;10:53-63.
14. Praetorius M, Limberger A, Müller M, Lehner R, Schick B, Zenner HP, Plinkert P, Knipper M. A novel microperfusion system for the long-Term local supply of drugs to the inner ear: implantation and function in the rat model. Audiol Neurootol. 2001;6:250-8. (Pubitemid 33135367)
15. Paasche G, Gibson P, Averbeck T, Becker H, Lenarz T, Stöver T. Technical report: modification of a cochlear implant electrode for drug delivery to the inner ear. Otol Neurotol. 2003;24:222-7. (Pubitemid 36337132)
16. Jolly C, MedEl. Implantable neuro-stimulation electrode with drug elution material. Patent US 2008/0033520 A1, 2008.
17. Dittrich B, Hammann D, Wenzel G, Möller M, Klee D. Dexamethasone releasing cylindrical polydimethyldisiloxane matrices. Biomaterialien (München). 2009;10:61.
18. Farahmand Ghavi F, Mirzadeh H, Imani M, Jolly C, Farhadi M. Corticosteroid-releasing cochlear implant: a novel hybrid of biomaterial and drug delivery system. J Biomed Mater Res B Appl Biomater. 2010;94:388-98.
19. Jolly C, Garnham C, Mirzadeh H, Truy E, Martini A, Kiefer J, Braun S. Electrode features for hearing preservation and drug delivery strategies. Adv Otorhinolaryngol. 2010;67:28-42.
20. Mohammad F, Maryam J, Pirooz S, Farahmand GF, Hesamedin E, Hamid M, Mohammad I, Jolly C. Dexamethasone eluting cochlear implant: Histological study in animal model. Cochlear Implants Int. 2012. doi:10.1179/17547628MY.0000000024.
21. Sternberg K, Kramer S, Nischan C, Grabow N, Langer T, Hennighausen G, Schmitz KP. In vitro study of drug-eluting stent coatings based on poly(L-lactide) incorporating cyclosporine A: drug release, polymer degradation and mechanical integrity. J Mater Sci Mater Med. 2007;18:1423-32.
22. Wadhwa R, Lagenaur CF, Cui XT. Electrochemically controlled release of dexamethasone from conducting polymer polypyrrole coated electrode. J Control Release. 2006;110:531-41.
23. Radeloff A, Unkelbach MH, Mack MG, Settevendemie C, Helbig S, Mueller J, Hagen R, Mlynski R. A coated electrode carrier for cochlear implantation reduces insertion forces. Laryngoscope. 2009;119:959-63.
24. Wefstaedt P, Scheper V, Lenarz T, Stöver T. Brain-derived neurotrophic factor/glial cell line-derived neurotrophic factor survival effects on auditory neurons are not limited by dexamethasone. NeuroReport. 2005;16:2011-4. (Pubitemid 41765701)
25. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47(1):175-81.
26. Lanzer P, Sternberg K, Schmitz KP, Kolodgie F, Nakazawa G, Virmani R. Drug-eluting coronary stent very late thrombosis revisited. Herz. 2008;33:334-42.
27. Kukreja N, Onuma Y, Daemen J, Serruys PW. The future of drug-eluting stents. Pharmacol Res. 2008;57:171-80.
28. Martin DP, Williams SF. Medical applications of poly-4-hydroxybutyrate: a strong flexible absorbable biomaterial. Biochem Eng J. 2003;16:97-105.
29. Dexamethason. Arzneistoff-Profile, Basisinformation über arzneiliche Wirkstoffe. Frankfurt am Main: GOVI-Verlag, Pharmazeutischer Verlag; 2009.